CLINICAL TRIALS PROFILE FOR NEXTERONE

All Clinical Trials for NEXTERONE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01401647 ↗	Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia	Completed	American Heart Association	Phase 3	2012-05-01	The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo.
NCT01401647 ↗	Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia	Completed	Canadian Institutes of Health Research (CIHR)	Phase 3	2012-05-01	The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo.
NCT01401647 ↗	Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia	Completed	Defence Research and Development Canada	Phase 3	2012-05-01	The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo.
NCT01401647 ↗	Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia	Completed	Heart and Stroke Foundation of Canada	Phase 3	2012-05-01	The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo.
NCT01401647 ↗	Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	2012-05-01	The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo.
NCT01401647 ↗	Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia	Completed	U.S. Army Medical Research and Development Command	Phase 3	2012-05-01	The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo.

Clinical Trial Conditions for NEXTERONE

Condition Name

Condition Name for NEXTERONE
Intervention	Trials
Atrial Fibrillation	2
Hepatitis C	1
Cardiac Arrest	1
Esophageal Carcinoma	1

Condition MeSH

Condition MeSH for NEXTERONE
Intervention	Trials
Atrial Fibrillation	2
Hepatitis C	1
Ventricular Fibrillation	1
Tachycardia, Ventricular	1

Clinical Trial Locations for NEXTERONE

Trials by Country

Trials by Country for NEXTERONE
Location	Trials
United States	9
Canada	1

Trials by US State

Trials by US State for NEXTERONE
Location	Trials
Oregon	2
New York	1
Wisconsin	1
Washington	1
Texas	1

Clinical Trial Progress for NEXTERONE

Clinical Trial Phase

Clinical Trial Phase for NEXTERONE
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for NEXTERONE
Clinical Trial Phase	Trials
Not yet recruiting	2
Completed	2

Clinical Trial Sponsors for NEXTERONE

Sponsor Name

Sponsor Name for NEXTERONE
Sponsor	Trials
Defence Research and Development Canada	1
Heart and Stroke Foundation of Canada	1
National Heart, Lung, and Blood Institute (NHLBI)	1

Sponsor Type

Sponsor Type for NEXTERONE
Sponsor	Trials
Other	7
NIH	2
U.S. Fed	2

Last updated: May 3, 2026

Clinical Trials Update, Market Analysis and Projection for NEXTERONE

No content is provided for “NEXTERONE” that identifies the active pharmaceutical ingredient, its indication(s), sponsor, trial identifiers, or regulatory status. A complete and accurate clinical trials update plus market analysis and projections cannot be produced without these facts.

What is NEXTERONE in the market and in the clinic?

NEXTERONE is not uniquely identifiable from the provided prompt. Multiple commercial and investigational products could share similar brand-like naming, and “Nexterone” is not mapped here to a specific drug substance, ATC/INN, MOA, or approved label.

Which clinical trials exist and what is their status?

No trial-level information (e.g., NCT/CTRI numbers, phases, recruitment status, endpoints, results, or timelines) is provided for NEXTERONE. Without verified trial identifiers and outcomes, a clinical trials update cannot be generated.

What is the market size and how does it trend?

No indication, geography, pricing basis, patient population, competitor set, or payer environment is provided for NEXTERONE. A market projection requires these anchors.

What are the drivers and blockers for uptake?

No label content, trial efficacy/safety profile, trial comparators, or dosing regimen is provided. Uptake drivers and barriers cannot be substantiated without these inputs.

What projection can be made for revenue and adoption?

No dosage form, route, target indication, expected launch date, pricing, reimbursement assumptions, or competitive dynamics are provided. Any numeric projection would be ungrounded.

Key Takeaways

• A clinical trials update cannot be produced because NEXTERONE is not uniquely identified and no trial identifiers or status data are supplied.
• A market analysis and numeric revenue projection cannot be produced because no indication, geography, comparator set, or commercial assumptions are supplied.
• No actionable, sourced business conclusions can be generated from the current prompt.

FAQs

1. What information is required to update NEXTERONE’s clinical development?
   Trial identifiers (e.g., NCT/CTRI), phase, indication, enrollment status, endpoints, and results.

2. What defines a credible market projection for a drug?
   Indication, epidemiology, competitor set, pricing, reimbursement, launch timing, and uptake curve assumptions tied to evidence.

3. How do I link “NEXTERONE” to the correct regulatory and trial records?
   Map the brand name to the INN/active ingredient and the sponsor’s development program.

4. Can projections be made without efficacy and safety outcomes?
   Not at an evidence-based level; uptake depends on trial outcomes and label scope.

5. What should be checked first for NEXTERONE?
   Approved label or investigational status, active ingredient identity, and the primary indication.

References

[1] No sources were provided or identified in the prompt.